New treatment to target mutant KRAS in tumors
Molecular brush-conjugated antisense oligonucleotide as a pan-KRAS depletion agent
['FUNDING_OTHER'] · PACDNA LLC · NIH-11180050
This study is testing a new treatment that uses a special type of medicine to target and reduce harmful proteins in certain cancers, aiming to make cancer treatment safer and more effective for patients with KRAS mutations.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | PACDNA LLC (nih funded) |
| Locations | 1 site (NATICK, UNITED STATES) |
| Trial ID | NIH-11180050 on ClinicalTrials.gov |
What this research studies
This research investigates a novel therapeutic approach using a special type of nucleic acid called Brushield™ conjugate to target and deplete mutant KRAS proteins, which are known to drive many human tumors. The study aims to enhance the effectiveness of antisense oligonucleotides by improving their stability and uptake in the body, allowing for lower dosages and reduced side effects compared to traditional treatments. By using advanced animal models, the research will optimize this treatment method before moving towards clinical applications. Patients may benefit from a more effective and safer treatment option for cancers driven by KRAS mutations.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with tumors that have KRAS mutations, particularly those with non-small cell lung cancer.
Not a fit: Patients without KRAS mutations or those with other types of cancer may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a more effective and safer treatment option for patients with cancers driven by mutant KRAS.
How similar studies have performed: Other research has shown promise in using nucleic acid therapeutics for cancer treatment, but this specific approach with Brushield™ conjugate is novel.
Where this research is happening
NATICK, UNITED STATES
- PACDNA LLC — NATICK, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: ZHANG, KE — PACDNA LLC
- Study coordinator: ZHANG, KE
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.